Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AC Immune (ACIU) Share-based Compensation: 2015-2025

Historic Share-based Compensation for AC Immune (ACIU) over the last 10 years, with Sep 2025 value amounting to $4.4 million.

  • AC Immune's Share-based Compensation rose 208.49% to $4.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.6 million, marking a year-over-year increase of 42.31%. This contributed to the annual value of $6.2 million for FY2024, which is 26.89% up from last year.
  • Latest data reveals that AC Immune reported Share-based Compensation of $4.4 million as of Q3 2025, which was up 222.39% from $1.4 million recorded in Q2 2025.
  • AC Immune's Share-based Compensation's 5-year high stood at $4.4 million during Q3 2025, with a 5-year trough of $574,678 in Q3 2022.
  • Its 3-year average for Share-based Compensation is $1.7 million, with a median of $1.4 million in 2024.
  • Its Share-based Compensation has fluctuated over the past 5 years, first slumped by 61.96% in 2022, then skyrocketed by 208.49% in 2025.
  • Over the past 5 years, AC Immune's Share-based Compensation (Quarterly) stood at $1.1 million in 2021, then decreased by 18.57% to $922,801 in 2022, then decreased by 2.63% to $898,502 in 2023, then grew by 22.85% to $1.1 million in 2024, then spiked by 208.49% to $4.4 million in 2025.
  • Its Share-based Compensation stands at $4.4 million for Q3 2025, versus $1.4 million for Q2 2025 and $1.7 million for Q1 2025.